

Histotripsy Ablation Alters the Tumor Microenvironment and Promotes Immune System Activation in a Subcutaneous Model of Pancreatic Cancer

Alissa Hendricks-Wenger¹, Jacqueline Sereno, Jessica Gannon, Allison Zeher, Rebecca M. Brock², Natalie Beitel-White³, *Student Member, IEEE*, Alexander Simon, Rafael V. Davalos⁴, *Member, IEEE*, Sheryl Coutermarsh-Ott, Eli Vlaisavljevich⁵, and Irving Coy Allen⁶

Abstract—Pancreatic cancer is a significant cause of cancer-related deaths in the United States with an abysmal five-year overall survival rate that is under 9%. Reasons for this mortality include the lack of late-

stage treatment options and the immunosuppressive tumor microenvironment. Histotripsy is an ultrasound-guided, noninvasive, nonthermal tumor ablation therapy that mechanically lyses targeted cells. To study the effects of histotripsy on pancreatic cancer, we utilized an *in vitro* model of pancreatic adenocarcinoma and compared the release of potential antigens following histotripsy treatment to other ablation modalities. Histotripsy was found to release immune-stimulating molecules at magnitudes similar to other nonthermal ablation modalities and superior to thermal ablation modalities, which corresponded to increased innate immune system activation *in vivo*. In subsequent *in vivo* studies, murine Pan02 tumors were grown in mice and treated with histotripsy. Flow cytometry and rtPCR were used to determine changes in the tumor microenvironment over time compared to untreated animals. In mice with pancreatic tumors, we observed significantly increased tumor-progression-free and general survival, with increased activation of the innate immune system 24 h posttreatment and decreased tumor-associated immune cell populations within 14 days of treatment. This study demonstrates the feasibility of using histotripsy for pancreatic cancer ablation and provides mechanistic insight into the initial innate immune system activation following treatment. Further work is needed to establish the mechanisms behind the immunomodulation of the tumor microenvironment and immune effects.

Manuscript received March 16, 2021; accepted May 1, 2021. Date of publication May 6, 2021; date of current version August 27, 2021. This work was supported in part by the Virginia-Maryland College of Veterinary Medicine, in part by the Virginia Tech Institute for Critical Technology and Applied Sciences Center for Engineered Health, and in part by the National Institutes of Health. (*Corresponding author: Alissa Hendricks-Wenger.*)

Alissa Hendricks-Wenger is with the Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA 24061 USA, also with the Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA 24061 USA, and also with the Graduate Program in Translational Biology, Medicine and Health, Virginia Tech, Roanoke, VA 24016 USA (e-mail: alissa94@vt.edu).

Jacqueline Sereno, Allison Zeher, and Sheryl Coutermarsh-Ott are with the Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA 24061 USA.

Jessica Gannon, Natalie Beitel-White, and Alexander Simon are with the Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA 24061 USA.

Rebecca M. Brock is with the Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA 24061 USA, and also with the Graduate Program in Translational Biology, Medicine and Health, Virginia Tech, Roanoke, VA 24016 USA.

Rafael V. Davalos is with the Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA 24061 USA, and also with the Center for Engineered Health, Institute for Critical Technology and Applied Sciences, Virginia Tech, Blacksburg, VA 24061 USA.

Eli Vlaisavljevich is with the Department of Biomedical Engineering and Mechanics, Virginia Tech, Blacksburg, VA 24061 USA, also with the Graduate Program in Translational Biology, Medicine and Health, Virginia Tech, Roanoke, VA USA, and also with the Center for Engineered Health, Institute for Critical Technology and Applied Sciences, Virginia Tech, Blacksburg, VA 24061 USA.

Irving Coy Allen is with the Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA 24061 USA, also with the Graduate Program in Translational Biology, Medicine and Health, Virginia Tech, Roanoke, VA USA, also with the Center for Engineered Health, Institute for Critical Technology and Applied Sciences, Virginia Tech, Blacksburg, VA 24061 USA, and also with the Department of Basic Science Education, Virginia Tech Carilion School of Medicine, Roanoke, VA 24016 USA.

This article has supplementary downloadable material available at <https://doi.org/10.1109/TUZZ.2019.2933787>, provided by the authors.

Digital Object Identifier 10.1109/TUFFC.2021.3078094

Index Terms—Biological effects & dosimetry, therapeutics.

I. INTRODUCTION

PANCREATIC cancer is the fourth leading cause of cancer-related deaths, with a 9% survival rate due to its late diagnosis and lack of curative treatment options [1], [2]. Standard treatment options are limited and include surgery, chemotherapy, and radiation [3]. Only 20% of patients have tumors that can be surgically removed, and of those patients, the cure rate is less than 25% [4]. Ablation procedures can act as a replacement for, or as an adjuvant to, surgery. The most commonly used ablation modalities for treating cancers in abdominal organs are radio frequency ablation (RFA), microwave ablation, high-intensity focused ultrasound (HIFU), and cryoablation. RFA is a thermal, minimally invasive ablation modality that utilizes high-frequency alternating currents

to thermally induce thermal necrosis [5]. Microwave ablation, also thermal and minimally invasive, induces cell death through electromagnetic microwaves that produce friction and heat [6]. HIFU ablates cells by depositing ultrasound energy at a focal point to rapidly increase tissue temperature [7]. Cryoablation results in tumor cell destruction through ice-crystal formation as a result of liquid nitrogen or argon gas delivered to the tissue and does not result in protein denaturation, which has led to increased reports of immunological effects compared to RFA and microwave ablation [5]. The thermal ablation modalities, although efficacious in treating certain malignancies, have not yet been ubiquitously accepted into clinics for pancreatic cancer therapy due to the risk of thermal damage to healthy pancreatic tissue, vasculature, and other critical structures.

Recent advancements have established nonthermal therapies that have the potential to treat pancreatic cancer. For example, irreversible electroporation (IRE) utilizes short, high-voltage electrical pulses that nonthermally open micropores in cell plasma membranes, inducing cell death [8]. Clinical trials have shown that IRE can ablate pancreatic tumors without damaging nearby critical structures and have had dramatic effects on patient survival that may be due to the induction of immunomodulatory mechanisms [9]–[14]. Given IRE's controlled cell death mechanisms, the procedure has been found to release immunostimulatory molecules and lead to a more immunologically active tumor microenvironment after treatment [15]. Furthermore, recent studies comparing the thermal ablation modalities, cryoablation, and IRE have found that the nonthermal modalities are more potent at stimulating an antitumor microenvironment [16]. These procedures still involve surgical incisions that increase the possibility of surgery-related injury or infection.

To address the clinical limitations of IRE and other ablation modalities, new focused ultrasound ablation methods have been studied as a completely noninvasive, nonthermal alternative. Histotripsy is a nonthermal, nonionizing, image-guided ablation modality that uses focused ultrasound to initiate acoustic cavitation, which leads to the lysis of cells contained in the targeted area [17], [18]. Ablation of internal targets with histotripsy is effective with little to no off-target effects [19]–[21]. Early studies with histotripsy ablation of melanoma, hepatocellular carcinoma, renal cell carcinomas, colorectal carcinomas, and neuroblastomas established that there is an activation of local, cellular, and systemic immune responses [22]–[27].

In this study, we assess the ability of histotripsy to ablate subcutaneous pancreatic tumors and determine the immunological changes within the treated tumors over time. First, we compared the release of damage-associated molecular patterns (DAMPs) known to activate the innate immune system and neoantigen generation following histotripsy against other tumor ablation modalities. We extended these *in vitro* findings using the *in vivo* Pan02 murine pancreatic cancer model. This mouse model was chosen given its well-characterized progression and described immune effects to cancer therapies [15], [28], [29]. Using this model, we demonstrate effective tumor ablation and proinflammatory changes in the

tumor microenvironment and identify critical immune signaling mechanisms associated with histotripsy treatment.

II. PROCEDURES

A. Tumor Injections and Monitoring

All *in vivo* experiments were conducted under institutional IACUC approval and following the NIH Guide for the Care and Use of Laboratory Animals. For these studies, male and female mice were equally utilized in the 7–10-week age range. Once the entire cohort of C57/B16 mice reached a minimum weight of 20 g, 100 μL of Pan02 cells (DTP and DCTD tumor repository) at a concentration of 6.0×10^7 cells/mL of Matrigel (Corning) were injected into the right flank of the mice that were anesthetized with vaporized isoflurane (1.5 L/min oxygen flow with 1%–3% isoflurane). Control animals were injected with the same amount of Matrigel that did not contain Pan02 cells. The mice were then monitored three times a week until the end of the study. Tumor diameters were measured with calipers and calculated as the square root of two perpendicular measurements, as previously described [24]. The weights and tumor sizes were recorded along with the general health of the mice.

B. Histotripsy Setup

In vivo studies used a custom 1-MHz, eight-element small animal histotripsy transducer with a geometric focus of 36 mm, an aperture size of 52.7 mm, and an f-number of 0.68. The full-width at half-maximum (FWHM) dimensions at a geometric focus of this transducer were 0.98, 0.93, and 3.9 mm in transverse, elevational, and axial, respectively. The transducer was driven via a custom high-voltage pulser designed to generate short therapy pulses of <2 cycles controlled by a field-programmable gate array (FPGA) board (Altera DE0-Nano Terasic Technology, Dover, DE, USA) programed for histotripsy therapy pulsing. The transducer was positioned in a tank of degassed water heated to 37 ± 4 °C beneath a custom-designed mouse surgical stage [see Fig. 1(a)] and attached to a computer-guided 3-D positioning system with a 0.05-mm motor resolution to control the automated volumetric treatments. A linear ultrasound imaging probe with a frequency range of 10–18 MHz (L18-10L30H-4, Teleded, Lithuania, EU) was coaxially aligned inside the transducer for treatment guidance and monitoring [20], [24]. The transducer was powered by a high-voltage dc power supply (GENH750W, TDK-Lambda), and the system was controlled using a custom user interface operated through MATLAB (MathWorks).

C. In Vitro Ablation Treatment Parameters

Pan02 cells transfected with a plasmid that produces the influenza antigen hemagglutinin (Pan02-HA) were used for these *in vitro* experiments. HA is a common surrogate used in tumor-specific antigen studies. Pan02-HA cells were ablated in four treatments and two levels of ablation [see Fig. 2(a)]. Cells were collected and centrifuged to pellet and were resuspended in PBS at a concentration of 10×10^6 cells/mL; 1 mL of cell




Fig. 1. *In vivo* experimental setup. (a) Murine histotripsy experiments were conducted using a 1-MHz transducer. (b) Timing for treatment, euthanasia, and data collection were set as diagramed. Days with histology collection are noted by cassettes, flash-frozen tumors noted by tubes with tumors, and serum noted by tubes with serum, and flow cytometry is noted by flow charts. Tumors located with ultrasound imaging were used for (c) planning automated ablation disks and (d) raster scan plots. (e) Therapy was guided by coaxially aligned ultrasound imaging. The red arrow indicates a bubble cloud that was generated during treatment.

suspension was used for each treatment. All samples were kept on ice until treatment. For all treatments, the partial ablation dosages were determined to be a successful ablation with >30% viability, and the full ablation dosages had <10% viability for all samples. For each ablation modality, the prefix “f-” is added before the modality name within the text to refer to the full ablation, and “p-” is added to refer to the partial ablation. For example, f-histotripsy is full ablation histotripsy and p-histotripsy is partial ablation histotripsy.

Histotripsy treatments were done in a custom holder [see Fig. 2(b)], utilizing the same 1-MHz transducer from the *in vivo* work at a PRF of 250 Hz at a single spot for 0.5 or 5 min. The movement of the transducer during treatment was not necessary given the circulation of the cell suspension

caused by histotripsy that was observed during treatment and in previous studies [30]. For cryoablation, cells were placed in liquid nitrogen (approximately -160°C) for 30 min. No lower dose was used given that any drop to therapeutically low temperatures (-20°C to -190°C) resulted in high levels of cell death [31]. Thermal ablation consisted of cells being kept at 80°C on a heating block for 1 or 30 min. The protocols for cryoablation and thermal ablation were based upon a previous study [16]. For samples not included in the analysis, the temperatures of the thermally treated samples were confirmed with a thermometer to reach 45°C , minimum temperature to be considered thermal ablation, within the first half of a minute and 80°C by 3 min [32]. Samples frozen with liquid nitrogen were assumed to surpass the therapeutic temperature threshold. Given the extensive prior studies showing no temperature change with IRE at the prescribed dosages or histotripsy, no temperature measurements were done for these therapies [17], [33]–[35]. For experimental sham, untreated control samples of cells were prepared and handled identically to treated samples but, instead of receiving treatment, remained on wet ice during the treatment of other cells.

For IRE treatments, cells were suspended in a sucrose solution, described previously to improve the quality of electrical transduction [36], and placed into 4 mm cuvettes. A generator (BTX ECM 830, Harvard Apparatus, Holliston, MA, USA) was used to apply 100 pulses with widths of $100\ \mu\text{s}$ at a frequency of 1 Hz and an electric field of either 500 or $2000\ \text{V}/\text{cm}$. Cells were then cultured for 24 h before supernatant collection to allow for the controlled cell death of IRE to take place [15]. Additional controls were collected at this point to accommodate for the extra downstream processing of the IRE samples. In these cases, the media that was used to culture the IRE samples overnight was also run through BCA and nanoprop. The resulting values from the controls were subtracted from the IRE samples to accommodate for the excess signaling caused by the media in culturing.

Viability for all modalities was determined shortly after treatment with standard Trypan Blue counting with a 1:40 dilution due to the high concentration of cells and calculated as a percentage of cells remaining viable after treatment. Post-ablation samples were centrifuged at $1000\times g$ for 5 min, and supernatants were collected. Supernatants for cryoablation, thermal ablation, and histotripsy were collected immediately after treatment and IRE 24 h after incubation at 37°C .

D. *In Vivo* Histotripsy Treatment

Mice were treated when the average tumor diameter of the cohort was approximately 0.6 cm, to ensure that the smallest tumors were large enough for targeting [see Fig. 1(b)]. Animals were euthanized 24 h after treatment, referred to as the acute group ($n = 7$ treated, $n = 7$ untreated controls, and $n = 3$ tumor-free untreated controls), or at survival time points, referred to as the chronic group ($n = 7$ treated, $n = 7$ untreated controls, and $n = 3$ tumor-free untreated controls) (see Table I). Euthanasia of chronic group animals, the point determined as their general survival, was determined




Fig. 2. (a) Treatment flow and dosages for various ablation modalities. (b) Histotripsy experiments on cell suspensions were conducted using a 1-MHz transducer.

TABLE I
SUBJECT NUMBERS PER EXPERIMENTAL GROUP

		Immediate Group	Acute Group	Chronic Group	Flow Cytometry
No Treatment	No Tumor	-	3	3	-
	Tumor	3	7	7	4/time point
Histotripsy Treated Tumors		3	7	7	4/time point

as either: 1) when clinical health evaluations found deleterious symptoms including hunching, irregular respiratory rate and rhythm, decreased alertness and socialization, or poor extremity utilization or 2) when the tumor diameter exceeded 1.4 cm. At necropsy, the immediate group ($n = 3$) mice that were treated and untreated (see Table I) were euthanized, and tumors were formalin fixed for histopathology to determine the efficacy of treatment. For the acute and chronic group mice, serum was collected, and the tumors were sectioned with a portion formalin-fixed for histopathology and another portion flash-frozen for mRNA analysis [see Fig. 1(b)].

Prior to each treatment, each mouse had fur removed over the tumors using the depilatory cream Nair (Naircare, Ewing, NJ, USA). Mice were anesthetized with vaporized 2%–4% isoflurane with an oxygen flow rate of 1.5 L/min. The mice were then placed on the subject stage with their tumor submerged in the degassed water in the subject stage's window. The tumor was located using the ultrasound imaging probe that was coaxially aligned to the histotripsy transducer and then targeted using an automated volumetric ablation algorithm that controlled the treatment following manual targeting.

For each tumor, a 3-D ellipsoidal volume was targeted using conservative margins of approximately 0.5–2 mm from the skin and underlying tissues (muscle, intestines, and so on). Since our automated treatment is a perfect ellipsoid and tumors are not, there was some small amount of variation between subjects. Using these margins, we intentionally targeted a partial ablation of approximately 60%–75% of the tumor

volume. This volume consisted of multiple, concentric 2-D elliptical slices. Each treatment slice was separated 0.75 mm apart. Within each slice, the area was populated with grid points separated 0.75 mm apart in the transverse direction and 1.25 mm apart in the axial direction [see Fig. 1(c)]. At each treatment point, histotripsy was applied at a pulse repetition frequency (PRF) of 250 Hz and a dwell time of 1 s, consequently sending 250 pulses to each point. For each slice, the automated treatment first generated a histotripsy bubble cloud at the center point of the slice and then scanned in a raster pattern to cover one half of the slice area. The transducer was then returned to the center of the ellipse and scanned in a raster pattern to cover the other half of the slice. Once a slice was scanned through completely, the system proceeds to the next slice, which is repeated until the entire ellipsoidal volume was treated. Throughout treatment, ultrasound guidance confirmed the location of the bubble cloud for the duration of the volumetric ablation [see Fig. 1(d)]. After treatment, the tumor volume was again imaged with ultrasound imaging in order to assess for tissue ablation.

E. Determining DNA Release and Quality

Each collected sample for each treatment group ($n = 5$ for the no treatment group and $n = 9-11$ /treatment group) was analyzed with a nanodrop drop, and the DNA concentrations ($\text{ng}/\mu\text{L}$) and the 260/280 absorbance ratios were recorded. Samples were then run on an ethidium bromide gel to visualize DNA strand sizes present in the samples utilizing a 100bp HyperLadder (Bioline) and following standard protocol.

F. Determining Protein Release and Quality

The protein released was quantified using a BCA assay (Thermo Scientific) following the manufacturer's protocol. Western blots were run using premade gels (Thermo Scientific) following standard protocols with 5 μg of protein/sample and transferred with the iBlot 2 Dry Blotting System (Thermo

Scientific). HA antigen release was determined using an HA antibody (Cell Signaling) as per the manufacturer's protocols. The protein's band area was quantified using iBright Analysis Software ($n = 5/\text{treatment group}$).

G. Histopathology

Tissues were harvested from animals and fixed in 10% formalin. Paraffin-embedded formalin-fixed tissues were stained with hematoxylin and eosin (H&E) following standard protocols. Evaluations were performed by trained individuals and independently verified by a blinded, board-certified veterinary pathologist (S.C.O.).

H. Profiling Gene Expression and Pathway Analysis

Using tumors flash-frozen from *in vivo* experiments, total RNAs are isolated from tumor samples using the RNeasy Mini Kit (250) (Qiagen), where the manufacturer's standard protocol was followed. RNA levels were quantified with a nanodrop, converted to cDNA, and were then pooled ($n = 7/\text{tumor group}$ and $n = 3/\text{control group}$). Pooled cDNA was placed into the commercially available pathway-focused array "Cancer Inflammation and Immunity Crosstalk" (SuperArrayTM platform; Qiagen) following the manufacturer's protocol (1/pooled groups). Fold change was determined using standard $\Delta\Delta\text{CT}$ calculations. Gene expression was analyzed using integrated pathway analysis (IPA, Qiagen) software to model changes in complex pathways [36].

I. Flow Cytometry Panel Staining

For immune cell profiling, additional mice were injected with tumors and taken down one, seven, and 14 days after treatment [see Fig. 1(b)] with an $n = 4$ per treated and untreated control group at each time point (see Table I).

After removal of the tumor, avoiding skin and fur, the tumor was placed into 8 mL of cold RPMI. Even though Pan02 tumors have microvasculature [37] because they are not very bloody due to total blood removal via heart stick, we did not perfuse the tissue before harvest or processing. The tissue was then mechanically digested and strained into a 50-mL conical tube. After centrifuging at 300xg for 10 min at 4 °C, the supernatant was discarded and the pellet resuspended in 10 mL of RPMI and was plated onto a 96-well V-bottom plate at a density of 1.0×10^6 cells/well. A 1:200 dilution of FACS buffer, sterile PBS with 2% FBS, 0.1% sodium azide, and anti-CD16/32 was added to the plate at a concentration of 50 $\mu\text{L}/\text{well}$. Antibodies were diluted with FACS buffer and added directly to the wells. The following antibodies were used: anti-CD8 SuperBright 645, anti-CD45 SuperBright 645, anti-CD11c APC, anti-CD45 PE, anti-F4/80 FITC, anti-CD4 PE.Cy5, anti-CD8 A488, anti-CD3 APC, anti-Ly6C APC Cy5, anti-Ly6G PE, and anti-FOXP3 PerCP Cy. Cells were washed with PBS and evaluated with FACS (BD Biosciences). Gating for specific immune cell populations is listed in Table II. It should be noted that the population "granulocytes" is likely to contain both granulocytic myeloid-derived suppresser cells and neutrophils [38], [39]. In addition, by gating macrophages as both CD11c and F4/80 that we are most likely focusing on

TABLE II
FLOW CYTOMETRY IMMUNE CELL MARKERS

IMMUNE CELL TYPE	IDENTIFYING MARKERS
Macrophages (MO)	CD45+ CD11c+ F4/80+ Ly6C-
Inflammatory Dendritic Cells (iDCs)	CD45+ CD11c+ F4/80- Ly6C+
Classic Dendritic Cells (cDCs)	CD45+ CD11c+ F4/80- Ly6C-
Monocytic Myeloid Derived Suppressor Cells (M-MDSC)	CD45+ CD11c- Ly6C+ Ly6G-
Granulocytes	CD45+ CD11c- Ly6C- Ly6G+
CD8+ T cells	CD45+ CD3+ CD4- CD8+
CD4+ T cells	CD45+ CD3+ CD4+ CD8-
T Regulatory Cells (Treg cells)	CD45+ CD3+ CD4+ CD8- FoxP3+
T Helper Cells (Th cells)	CD45+ CD3+ CD4+ CD8- FoxP3-

a subpopulation of macrophages, more extensive panels would be necessary to confirm the ratio of subpopulations.

J. HMGB1 Serum ELISA

Serum levels of high mobility group protein (HMGB1) in acute and survival group mice were determined utilizing an ELISA assay kit (ABclonal) following the manufacturer's suggested protocol.

K. Statistics

Data were analyzed using GraphPad Prism, version 8. Statistical significance was defined as $p \leq 0.05$, where values were not significant, but $p < 0.20$, where the value is noted in the text. All data are represented as the mean \pm SEM. A student's two-tailed t-test was used when comparing two experimental groups. When many t-tests were performed for one graph, group letter designations were used. Lowercase letters on top of bars indicate significance; bars with the sample letter designation are not significant, while those that do not share a letter are significant ($p < 0.05$). Multiple comparisons were done using one- or two-way ANOVA where appropriate and then followed by the Tukey posttest for multiple pairwise examinations.

III. RESULTS

A. Different Ablation Modalities Show Differential Release of Damage Associated Molecular Patterns (DAMPs) and Potential Antigens

Pan02-HA cells were treated with thermal ablation, cryoablation, IRE, and histotripsy at full (f-) and partial (p-) doses and were chosen based on previous literature [see Fig. 2(a)] [16]. Treatments that lead to less than 10% viability in all samples were considered fully ablated, and those that were greater than 30% in all samples were considered partially ablated [see Fig. 3(a)]. All samples' lysates were analyzed for peptide and DNA nucleotide release ($n = 5$ for no treatment and $n = 9-11$ for treatment groups).

Extracellular DNA is a DAMP and often correlates with extracellular nuclear proteins, such as HMGB1, which also acts as robust damage signaling. Here, we observed increased levels of DNA for all treatments compared to untreated




Fig. 3. (a) Cell suspension ablations resulted in partial and full ablations. DNA release was (b) quantified and (c) visualized. (d) Protein release was quantified, and (e) relative release of the antigen HA was quantified from western blot bands. Lowercase letters on top of bars indicate significance; bars with the sample letter designation are not significant, while those that do not share a letter are significant ($p < 0.05$).

samples [see Fig. 3(b)]. DNA release was evaluated by nucleotide quantification, which showed f-IRE (470.73 ± 283.34 ng/ml) to have a significantly ($p < 0.05$) higher concentration than most other modalities, excluding f-cryoablation (262.49 ± 159.00 ng/ml) and f-histotripsy (315.71 ± 175.28 ng/ml). P-thermal (177.33 ± 113.15 ng/ml), f-thermal (170.48 ± 72.20 ng/ml), p-IRE (179.82 ± 141.98 ng/ml), and p-histotripsy (165.03 ± 83.09 ng/ml) were all similar to each other. Only f-IRE and f-histotripsy were significantly greater than the untreated control samples (20.35 ± 10.11 ng/ml). Gel electrophoresis showed that cryoablation and both dosages of histotripsy left large segments of detectable DNA, while untreated, IRE, and thermally ablated samples produced no visible bands [see Fig. 3(c)].

Peptide release, which correlates with potential antigens, was observed to be released significantly in nonthermal ablation modalities [see Fig. 3(d)]. There was no significant difference between p-thermal (383.8 ± 345.4 μ g/ml) or f-thermal (443.3 ± 255.8 μ g/ml) ablation's peptide release from samples that were not treated (194.5 ± 50.7 μ g/ml). On the other hand, f-IRE (2113 ± 409.1 μ g/ml) and f-histotripsy (2208 ± 751.8 μ g/ml) were significantly ($p < 0.05$) higher levels of release compared to all other modalities, except for p-IRE (1869 ± 431.3 μ g/ml). F-cryoablation (1512 ± 415.4 μ g/ml) and p-histotripsy (1300 ± 490.0 μ g/ml) were significantly different from the low (significance group "a") and high release clusters (significance group "c").

Release of HA was confirmed on western blot for all treated samples, regardless of ablation treatment (see Fig. 1 in the

Supplementary Material). The average area of the various treatments HA bands was not significantly different between any therapies compared to each other nor the untreated samples (297.6 ± 39.3 units) [see Fig. 3(e)]. The highest detection of HA was found in p-thermal treated samples (367.8 ± 24.25 units), followed by p-histotripsy (344.3 ± 38.5 units) and f-histotripsy (340.0 ± 35.2 units). F-cryoablation (332.0 ± 56.4 units), f-thermal (320.3 ± 33.1 units), p-IRE (322.0 ± 26.4 units), and f-IRE (317.2 ± 24.2 units) were all found to have larger bands than no treatment and smaller than p-thermal, p-histotripsy, and f-histotripsy.

B. Histotripsy Is an Effective Tumor Ablation Modality in the Subcutaneous Pan02 Model

The schematic shows the custom histotripsy rig and automated ablation procedure that was used for *in vivo* treatments (see Fig. 1). Coaxial ultrasound imaging confirmed the presence of a bubble cloud within the tumors during treatment [see Fig. 1(e)]. Mice were treated when tumors reached 0.6 cm in diameter on average and harvested in groups, as depicted in Fig. 1(b). Ablation of tumors was confirmed with ultrasound, with increased hypoechoic regions and histopathology, where a partial ablation of tumors with viable tumor tissue on margins and in islands within the ablation zone was observed (see Fig. 4). On ultrasound images, the center of the treated region had a more notable decrease in ultrasound reflection, while the dermal margin maintained a comparable hyperechocytivity after treatment compared to before [see Fig. 4(a) and (b)]. This pattern was also noted in histopathology. The center




Fig. 4. Ultrasound images of tumor (a) before and (b) after treatment, exhibiting more hypoechoic central region posthistotripsy. Orange shapes on ultrasound indicate the location of tumors. Green circles indicate the location of bubble cloud determined in water prior to treatment and were utilized for treatment planning. Histology to tumors (c) without and (d) with treatment shows decreased cellular detail after treatment. The dotted black line outlines the necrotic core of the tissue. Scale bar on H&E images = 500 μm .

of untreated tumors has a characteristic necrotic core [see Fig. 4(c)], and the treated tumors appeared to have a larger region of cell death that extends nearly to the margins of the tumor [see Fig. 4(d)].

Calculated tumor diameters decreased for a few days after the partial ablation with histotripsy and maintained size for two weeks before resuming tumor growth [see Fig. 5(a)]. The average tumor size of untreated tumors continued to increase in size at a relatively steady rate [see Fig. 5(a)]. The greatest difference between the treated and untreated groups was reached on day 15, eight days posttreatment when the treated tumors were 43% of the size of the untreated tumors on average. Compared to the untreated mice, histotripsy treatment increased tumor-progression-free survival by 19 days from ten to 29 days posttreatment [see Fig. 5(b)] and general survival by eight days from 43 to 51 days posttreatment [see Fig. 5(c)].

C. Histotripsy Ablation Results in Increased Acute Cellular Immune Response

These tumors even without treatment tend to develop a central area of necrosis as they progress. These necrotic cores are often characterized by accumulations of cell debris with variable numbers of infiltrating degenerate and nondegenerate neutrophils. Otherwise, appreciable numbers of immune cells are relatively absent microscopically throughout the tumor tissue [see Fig. 6(a)]. Treated tumors also exhibited a core

of cell death following ablation with variable infiltration by predominantly degenerate neutrophils. However, in addition to cellular debris, these cores also often contain ghost cells and acute hemorrhage [see Fig. 6(b)]. In both treated and untreated tumors, small to moderate numbers of neutrophils, macrophages, lymphocytes, and/or plasma cells are present at the tumor periphery. There is no appreciable difference between the two [see Fig. 6(c) and (d)].

Despite the lack of appreciable differences in immune cell populations microscopically, we investigated immune cell signaling through gene expression. Superarray rtPCR showed that many genes associated with cancer inflammation and immunity crosstalk were significantly regulated after histotripsy treatment (see Table I in the Supplementary Material). The IPA analysis comparing treated animals to untreated in acute and survival groups found multiple canonical immune pathways regulated by histotripsy treatment [see Fig. 6(a)]. As a trend, the proinflammatory pathways are upregulated 24-h treatment, but the majority of these pathways become downregulated and were replaced with more anti-inflammatory pathways at survival points. Many of the upregulated pathways (HMGB1, NF- κ B, IL-6, and TLR signaling pathways) are interconnected and are self-regulated to decrease in function over time [see Fig. 6(b)]. The schematic in Fig. 5 illustrates the interactions and mechanisms identified by IPA that is upregulated in the acute treatment




Fig. 5. After treatment of tumors on day 8, as indicated by the black arrow, the reduction of tumor volume was indicated by (a) caliper measurements. Changes in health observed in (b) tumor-progression-free survival and (c) general survival.

group and downregulated in the survival group. Some of these proteins and pathways were not directly analyzed but are predicted to be modulated based upon molecules that are upstream and downstream by IPA. Together, these data indicate a significant upregulation of pathways associated with the activation of the innate immune system associated with DAMP signaling.

HMGB1 signaling was identified by IPA and is a potent DAMP. To verify this aspect of our pathway analysis, we evaluated the protein levels of HMGB1 in the serum with and without histotripsy treatment. Consistent with the IPA results, HMGB1 levels were increased in the sera of treated mice at the acute time point compared to untreated and control animals, while both treated and untreated mice saw a significant ($p < 0.05$) decrease in serum HMGB1 levels at survival endpoints [see Fig. 6(c)]. Although there was a notable increase, due to the significantly higher variance ($p = 0.0032$), there was no significance in the average serum HMGB1 level in the treated acute group compared to the untreated and control groups.

D. Histotripsy Alters Immune Cell Composition in the Tumor Microenvironment

To quantify changes in immune cell populations within tumors overtime after histotripsy treatment, tumors were collected 24 h and seven and 14 days after treatment for

flow cytometry. Although there were no significant changes at the 24-h time point, there was an appreciable decrease in inflammatory dendritic cells (iDCs, $p = 0.19$), classical dendritic cells (cDCs, $p = 0.18$), granulocytes, Th cells, CD4+ T cells, and CD8+ T cell populations after treatment (see Figs. 6 and 7). The relative reduction of iDCs ($p = 0.13$) and cDCs ($p = 0.07$) continued to day 7 along with a decrease in M-MDSCs; at this point, the remaining cells that appeared reduced at 24 h were more comparable to the untreated (see Fig. 7). At 14 days after treatment, macrophages and Treg cells were found to be significantly reduced, while cDCs were found to be significantly increased, and neutrophils ($p = 0.19$) notably increased in treated tumors compared to the untreated (see Fig. 7 and 8). While there were no changes in the ratios of CD4+/CD8+ T cells in the treated tumors compared to the untreated, there were significant increases in CD4+ and a notable increase in CD8+ T cells within the treated tumors at seven days after treatment (see Fig. 8).

IV. DISCUSSION

This study investigated the treatment of pancreatic tumors with histotripsy and the resultant immunological responses, with a focus on the innate immune system. To optimize our immune system assessments, we established conservative margins with the expectation that some tumors would not be treated. This allowed cells within the untreated margins to




Fig. 6. We initially chose to investigate changes in immune cell infiltration following histotripsy treatment by evaluating the tissues microscopically. (a) Untreated tumors exhibit necrotic cores as part of the natural progression of the tumor. These are characterized by predominantly lytic cellular debris but also often contain variable numbers of degenerate and non degenerate neutrophils (asterisk). (b) Treated tumors likewise develop similar foci of necrosis with lytic debris and variable neutrophilic infiltration. In addition, they also exhibit ghost cells which are eosinophilic (pink) remnants of dead cells (arrows) as well as hemorrhage (not shown). In addition, both untreated (c) and treated (d) tumors exhibit a mixture of inflammatory cells at the periphery of the tumor. Microscopically there are no appreciable differences between infiltration of these inflammatory cells between untreated and treated tumors. Analysis of mRNA expression in treated tumors showed regulation of immune pathways (e). Regulated pathways interact with each other and are up regulated in the acute group and downregulated in the chronic group (f). Serum HMGB-1 levels (g) correlate with the mRNA upregulation of HMGB-1 associated pathways.

respond to the effects of our treatment and provided specimens for subsequent analysis. For *in vivo* ablations, histotripsy treatment was confirmed via bubble-cloud formation, while H&E showed complete ablation within targeted regions. Overall, we achieved a partial ablation of all treated tumors. There was an average reduction of 43% in the tumor diameters of the remaining tumor tissue after treatment, comparable to tumor retardation compared to previous histotripsy subcutaneous tumor treatments [20], [23], [24]. Based upon the fully ablated tissue found within the targeted regions on H&E, the remaining tissue can be assumed to have been untreated based upon the margins set. This led to tumors that were fully ablated in certain regions and completely untreated in others. More complete ablation of tumors with histotripsy has been achieved in *de novo* and *in situ* studies where margins include surrounding healthy tissues, but these tumors still recurred [40]–[43]. In this study, the progression of tumor growth was improved with treatment [see Fig. 5(b)]. However, in line with previous studies, tumor recurrence occurred and minimized the improvement of the general survival for animals that received treatment [see Fig. 5(c)].

The release of DAMPs is a consistent feature of focal ablation modalities, and the established modalities have been compared to each other in previous work [16]. Histotripsy has not been previously, directly compared to nonultrasonic ablation modalities. The effects of histotripsy compared to other ablation modalities for producing immune-stimulating molecules are of interest given that the response to the histotripsy treatment of pancreatic tumors *in vivo* yielded an inflammatory response that is turned off over time while showing relatively large variations of immune cell proportions within treated tumors. Looking at the release of DNA and peptides as potential DAMPs showed that histotripsy is comparable to the nonthermal ablations cryoablation and IRE (see Fig. 3).

Extracellular DNA is recognized by innate immune system receptors as a DAMP and is not typically found in the absence of damage [44]. In addition, the presence of released proteins increases the probability of the immune system being recruited by damage associated cytokines and antigens. Our hypothesized expectations for the *in vitro* studies were that cryoablation and histotripsy should have similar, more intact DNA, in




Fig. 7. Single-cell suspension from treated and untreated tumors were collected at 24 h and seven and 14 days after treatment and were stained as described for flow cytometry to identify innate immune cells. The percentage of each innate immune cell population analyzed was calculated as part of the total CD45+ cells stained. Example flow cytometry plots from treated and untreated tumors at 14 days after treatment.

larger fragments, and more protein released from cells after ablation given that they both ablate cells through immediate lysis [17], [45]. On the other hand, no cell death was observed in untreated cells, also as expected, and therefore, had low levels of protein and DNA. However, IRE induces a delayed cell death, defined as either apoptosis or pyroptosis [15]. DNA fragmentation and protein release or damage are hallmark features of programmed cell death. Similarly, thermal ablation is known to directly denature DNA and protein [16], [46]. Thus, in both these cases, we predicted that the DNA released following ablation would be significantly more fragmented, including significantly smaller and undetectable fragments. Even though IRE does use a delayed cell death mechanism, we did expect to find the higher level of detectable proteins, given that programmed cell death does not denature all of the released proteins and previous studies that also showed that IRE can release a significant magnitude of intact proteins [15], [16].

In addition, results from the *in vitro* experiments provide important comparisons between different ablation methods and demonstrate that nonthermal ablation approaches, including histotripsy, lead to significantly increased release of DAMPs

and potential antigens in comparison to thermal ablation methods. In comparing the clinical relevance of the differential release of DAMPs and potential antigens that was observed between the ablation modalities *in vitro*, it is important to note that additional *in vivo* studies will be needed to further study the differences between each ablation modality. Similarly, additional *in vivo* studies will be needed to further investigate the role of treatment dose in immune system activation for each of the ablation modalities. For instance, it is not clear whether the partial ablations generated in our *in vitro* studies will be representative of a partial or incomplete ablation in a clinical setting. For the thermal ablation, cryoablation, and IRE samples treated at partial-ablation doses in this study *in vitro*, all of the cells in suspension were treated at a reduced magnitude. In contrast, since histotripsy is a binary treatment that requires a bubble cloud to be formed, once a distinct pressure threshold has been exceeded [47]–[50], the histotripsy partial ablation resulted in only a portion of the cells being exposed to a full amplitude histotripsy bubble cloud, whereas the remaining cells received no treatment. When comparing these *in vitro* results from cell suspensions to *in vivo* ablations, it is important to remember that these differences in how a




Fig. 8. Single-cell suspension from treated and untreated tumors were collected at 24 h and seven and 14 days after treatment and were stained as described for flow cytometry to identify adaptive immune cells. The percentage of each adaptive immune cell population analyzed was calculated as part of the total viable cells stained (gated as singlets). The ratio of CD4+/CD8+ T cells was calculated as a simple ratio. Example flow cytometry plots from treated and untreated tumors at 14 days after treatment.

partial ablation versus a full ablation is acquired may result in different responses. As a result, controlled *in vivo* studies comparing the effects of different ablation modalities and different treatment doses on the potential immunological benefits should be conducted. In addition to comparing the differences between partial and complete ablation, these future studies should investigate the potential risks of overtreatment that could potentially reduce immunological benefits. For instance, in prior work designing IRE protocols, users have outlined specific treatment guidelines to avoid excessive Joule heating to capitalize on the therapeutic benefits of the nonthermal IRE ablation [34]. Similarly, samples overtreated with thermal ablation modalities and cryoablation face an increased rate of macromolecule breakdown and protein denaturation compared to nonthermal [16]. Future studies are needed to determine any effects of overtreatment with histotripsy and to determine the optimal histotripsy treatment strategies for maximizing immunological benefits.

Given that histotripsy's mechanism of ablation is the mechanical lysis of cells and that, *in vitro*, we found the increased release of DNA and proteins (see Fig. 3), the determination that DAMP signaling pathways [see Fig. 5(f)] were

activated *in vivo* was not surprising. Although we did not appreciate histological changes in immune cell infiltration on a microscopic level, gene expression analysis suggested changes in immune cell signaling pathways, which led us to assess immune cell populations via flow cytometry, a more sensitive indicator. Here, we were able to identify specific pathways modulated by histotripsy, including HMGB1, IL-6, Interferon, TEC Kinase, JAK/STAT, and PPAR pathway signaling. These pathways are consistent with responses to trauma or physical damage [51]–[53]. As time passes after trauma, these signaling pathways become repressed to control the immune response. One way by which this is done is through the PPAR pathway, which can inhibit the downstream production of cytokines from the HMGB1 and NF- κ B pathways [54]. The activation of the PPAR pathway can also increase healing effects by stimulating the production of VEGF [55], found in our study to be significantly increased in treated survival group tumors (see Fig. 5(f), and see Table I in the Supplementary Material). For healing, the production of VEGF is needed to reestablish healthy vasculature; however, high levels of VEGF within a tumor have been established to be tumorigenic and correlates with poor patient outcomes [56]. Histotripsy increasing the

activation of the PPAR pathway and increasing the levels of VEGF expression did not promote negative outcomes for the animals in our study but could be targets of future adjuvants to extend the early inflammatory tumor microenvironment.

At two weeks posthistotripsy ablation, there was a significant decrease in macrophages (see Fig. 6) and Treg cells (see Fig. 7). Significant decreases in the expression of cytokines are associated with tumor-associated macrophages (TAMs), including IL-4, IL-10, CCL-2, CCL-22, and CXCL-12 (see Table I in the Supplementary Material), and suggest that the reduction in macrophages within the treated tumors could be indicative of a decrease in TAMs [57], [58]. A decrease in Treg cells with a potential decrease in TAMs could indicate additional access of histotripsy immunomodulation of the tumor microenvironment to being less anti-inflammatory. This could be a potential target for enhancement with adjuvant therapies [57], [59]. Overall, these changes to immune cell populations should be further analyzed in future studies to determine the full extent of changes to subpopulations, such as changes to M1/M2/TAM macrophages instead of basic populations shown here.

Early studies investigating the immunological effects of histotripsy compared the effects of acoustic cavitation to acoustic heating with thermal HIFU. One study using a subcutaneous colon adenocarcinoma mouse model showed that histotripsy is capable of stimulating CD11c+ cells within the tumors more than thermal HIFU [26]. It has also been shown that histotripsy of murine melanoma can better stimulate an immune response with a decrease in metastasis in the weeks following treatment compared to HIFU, suggesting the involvement of antitumor lymphocytes [27]. More recent studies have further established the proinflammatory local and systemic effects of histotripsy on the immune response in melanoma, neuroblastoma, hepatocellular carcinoma, and renal cell carcinoma [22]–[24]. This study adds to this knowledge by establishing a framework for the immune response to histotripsy ablation of pancreatic cancer. The response reestablished here is similar to other studies. However, given that the Pan02 tumors are known to be poorly immunogenic [60], it was not surprising that the local changes in immune cell populations, while significant at points (see Figs. 7 and 8) were not as prominent of a profile shift as what has been reported in other tumor types. Using the Pan02 model, a prior study with IRE showed that subcutaneous tumors did not have a strong change in immune cell populations within the tumor as orthotopic tumors [61]. Similar to the current work, this prior study showed data that the non-thermal ablation of the subcutaneous pancreatic tumors can shift the tumor microenvironment to being more pro-inflammatory [61].

The results of this study provide evidence that histotripsy can ablate subcutaneous pancreatic tumors and stimulate a local immune response. This study builds upon previous studies utilizing histotripsy for other tumor types [20], [22]–[24] and shows a potential immune profile for pancreatic tumors after histotripsy ablation. Overall, the results of this work provide a baseline expectation of the response of pancreatic tumors to histotripsy, which will help for planning future orthotopic studies.

V. CONCLUSION

This study demonstrates the feasibility of using histotripsy for pancreatic cancer ablation and defines mechanisms associated with innate immune system activation following treatment. Further work is needed to establish the mechanisms behind the immunomodulation of the tumor microenvironment and its systemic effects.

ACKNOWLEDGMENT

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health (NIH) or any other funding agency. Figs. 1(b) and 6(f) were created using biorender.com.

REFERENCES

- [1] R. L. Siegel, K. D. Miller, and A. Jemal, "Colorectal cancer statistics, 2017," *CA, Cancer J. Clin.*, vol. 67, no. 1, pp. 177–193, Jan. 2017.
- [2] R. L. Siegel, K. D. Miller, and A. Jemal, "Colorectal cancer statistics, 2020," *CA, Cancer J. Clin.*, vol. 70, no. 4, pp. 145–164, 2020.
- [3] H. Manuel, "Pancreatic cancer," *New England J. Med.*, vol. 362, no. 17, pp. 1605–1617, 2010.
- [4] S. Gillen, T. Schuster, C. M. zum Bäschenfelde, H. Friess, and J. Kleeff, "Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages," *PLoS Med.*, vol. 7, no. 4, Apr. 2010, Art. no. e1000267.
- [5] O. Kepp, A. Marabelle, L. Zitvogel, and G. Kroemer, "Oncolysis without viruses—Inducing systemic anticancer immune responses with local therapies," *Nature Rev. Clin. Oncol.*, vol. 27, pp. 49–64, Jan. 2019.
- [6] C. J. Simon, D. E. Dupuy, and W. W. Mayo-Smith, "Microwave ablation: Principles and applications," *RadioGraphics*, vol. 25, no. 1, pp. S69–S83, Oct. 2005.
- [7] Y. Keisari, "Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation," *Front Biosci.*, vol. 22, pp. 310–347, Oct. 2017.
- [8] R. V. Davalos, L. Mir, and B. Rubinsky, "Tissue ablation with irreversible electroporation," *Ann. Biomed. Eng.*, vol. 33, no. 2, p. 223, 2005.
- [9] R. C. G. Martin *et al.*, "Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: Safety and efficacy," *Ann. Surg.*, vol. 262, no. 3, pp. 486–494, 2015.
- [10] H. J. Scheffer *et al.*, "Ablation of locally advanced pancreatic cancer with percutaneous irreversible electroporation: Results of the phase I/II PANFIRE study," *Radiology*, vol. 282, no. 2, pp. 585–597, Feb. 2017.
- [11] M. P. Belfiore *et al.*, "Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: Our preliminary experience," *Int. J. Surg.*, vol. 21, pp. S34–S39, Sep. 2015.
- [12] H. J. Scheffer *et al.*, "Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor t cell activation," *Oncol Immunology*, vol. 8, no. 11, Nov. 2019, Art. no. 1652532.
- [13] R. C. G. Martin *et al.*, "Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery," *J. Surg. Oncol.*, vol. 114, no. 7, pp. 865–871, Dec. 2016.
- [14] N. Beitel-White, R. C. G. Martin, Y. Li, R. M. Brock, I. C. Allen, and R. V. Davalos, "Real-time prediction of patient immune cell modulation during irreversible electroporation therapy," *Sci. Rep.*, vol. 9, no. 1, Art. no. 17739, Nov. 2019, doi: 10.1038/s41598-019-53974-w.
- [15] R. M. Brock, N. Beitel-White, R. V. Davalos, and I. C. Allen, "Starting a fire without flame: The induction of cell death and inflammation in electroporation-based tumor ablation strategies," *Frontiers Oncol.*, vol. 10, Jul. 2020.
- [16] Q. Shao *et al.*, "Engineering t cell response to cancer antigens by choice of focal therapeutic conditions," *Int. J. Hyperthermia*, vol. 36, no. 1, pp. 130–138, Jan. 2019.
- [17] K. B. Bader, E. Vlasisavljevich, and A. D. Maxwell, "For whom the bubble grows: Physical principles of bubble nucleation and dynamics in histotripsy ultrasound therapy," *Ultrasound Med. Biol.*, vol. 45, no. 5, pp. 1056–1080, May 2019.

- [18] E. Vlaisavljevich, A. Maxwell, L. Mancia, E. Johnsen, C. Cain, and Z. Xu, "Visualizing the histotripsy process: Bubble cloud-cancer cell interactions in a tissue-mimicking environment," *Ultrasound Med Biol.*, vol. 42, no. 10, pp. 2466–2477, Jul. 2016, doi: [10.1016/j.ultrasmedbio.2016.05.018](https://doi.org/10.1016/j.ultrasmedbio.2016.05.018).
- [19] E. Vlaisavljevich *et al.*, "Non-invasive ultrasound liver ablation using histotripsy: Chronic study in an *in vivo* rodent model," *Ultrasound Med. Biol.*, vol. 42, no. 8, pp. 1890–1902, Aug. 2016.
- [20] T. Worlikar *et al.*, "Histotripsy for non-invasive ablation of hepatocellular carcinoma (HCC) tumor in a subcutaneous xenograft murine model," in *Proc. 40th Annu. Int. Conf. IEEE Eng. Med. Biol. Soc. (EMBC)*, Jul. 2018, pp. 6064–6067.
- [21] K. C. Longo *et al.*, "Robotically assisted sonic therapy (RAST) for noninvasive hepatic ablation in a porcine model: Mitigation of body wall damage with a modified pulse sequence," *CardioVascular Interventional Radiol.*, vol. 42, no. 7, pp. 1016–1023, Jul. 2019, doi: [10.1007/s00270-019-02215-8](https://doi.org/10.1007/s00270-019-02215-8).
- [22] G. R. Schade, Y.-N. Wang, S. D'Andrea, J. H. Hwang, W. C. Liles, and T. D. Khokhlova, "Boiling histotripsy ablation of renal cell carcinoma in the eker rat promotes a systemic inflammatory response," *Ultrasound Med. Biol.*, vol. 45, no. 1, pp. 137–147, Jan. 2019.
- [23] A. Eranki *et al.*, "High-intensity focused ultrasound (HIFU) triggers immune sensitization of refractory murine neuroblastoma to checkpoint inhibitor therapy," *Clin. Cancer Res.*, vol. 26, no. 5, pp. 1152–1161, Mar. 2020.
- [24] S. Qu *et al.*, "Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy," *J. Immunotherapy Cancer*, vol. 8, no. 1, Jan. 2020, Art. no. e000200.
- [25] K. J. Pahk *et al.*, "Boiling histotripsy-induced partial mechanical ablation modulates tumour microenvironment by promoting immunogenic cell death of cancers," *Sci. Rep.*, vol. 9, no. 1, Dec. 2019, Art. no. 9050.
- [26] Z. Hu *et al.*, "Investigation of HIFU-induced anti-tumor immunity in a murine tumor model," *J. Translational Med.*, vol. 5, no. 1, p. 34, 2007.
- [27] Y. Xing, X. Lu, E. C. Pua, and P. Zhong, "The effect of high intensity focused ultrasound treatment on metastases in a murine melanoma model," *Biochem. Biophysical Res. Commun.*, vol. 375, no. 4, pp. 645–650, Oct. 2008.
- [28] M. E. Lorkowski *et al.*, "Immunostimulatory nanoparticle incorporating two immune agonists for the treatment of pancreatic tumors," *J. Controlled Release*, vol. 330, pp. 1095–1105, Feb. 2021, doi: [10.1016/j.jconrel.2020.11.014](https://doi.org/10.1016/j.jconrel.2020.11.014).
- [29] C. C. Baniel *et al.*, "In situ vaccine plus checkpoint blockade induces memory humoral response," *Frontiers Immunol.*, vol. 11, p. 1610, Jul. 2020, doi: [10.3389/fimmu.2020.01610](https://doi.org/10.3389/fimmu.2020.01610).
- [30] A. D. Maxwell, C. A. Cain, A. P. Duryea, L. Yuan, H. S. Gurm, and Z. Xu, "Noninvasive thrombolysis using pulsed ultrasound cavitation therapy-histotripsy," *Ultrasound Med. Biol.*, vol. 35, no. 12, pp. 1982–1994, Dec. 2009.
- [31] B. M. Aarts *et al.*, "Cryoablation and immunotherapy: An overview of evidence on its synergy," *Insights Imag.*, vol. 10, no. 1, pp. 1–12, Dec. 2019.
- [32] C. Brace, "Thermal tumor ablation in clinical use," *IEEE Pulse*, vol. 2, no. 5, pp. 28–38, Sep. 2011, doi: [10.1109/mpul.2011.942603](https://doi.org/10.1109/mpul.2011.942603).
- [33] M. Faroja *et al.*, "Irreversible electroporation ablation: Is all the damage nonthermal?" *Radiology*, vol. 266, no. 2, pp. 462–470, Feb. 2013.
- [34] R. V. Davalos, S. Bhonsle, and R. E. Neal, "Implications and considerations of thermal effects when applying irreversible electroporation tissue ablation therapy," *Prostate*, vol. 75, no. 10, pp. 1114–1118, Jul. 2015.
- [35] R. M. Brock *et al.*, "Patient derived xenografts expand human primary pancreatic tumor tissue availability for ex vivo irreversible electroporation testing," *Frontiers Oncol.*, vol. 10, May 2020.
- [36] V. M. Ringel-Scaia *et al.*, "High-frequency irreversible electroporation is an effective tumor ablation strategy that induces immunologic cell death and promotes systemic anti-tumor immunity," *EBioMedicine*, vol. 44, pp. 112–125, Jun. 2019, doi: [10.1016/j.ebiom.2019.05.036](https://doi.org/10.1016/j.ebiom.2019.05.036).
- [37] M. Kato, K. Watabe, M. Tsujii, T. Funahashi, I. Shimomura, and T. Takehara, "Adiponectin inhibits murine pancreatic cancer growth," *Digestive Diseases Sci.*, vol. 59, no. 6, pp. 1192–1196, Jun. 2014.
- [38] J.-I. Youn and D. I. Gabrilovich, "The biology of myeloid-derived suppressor cells: The blessing and the curse of morphological and functional heterogeneity," *Eur. J. Immunol.*, vol. 40, no. 11, pp. 2969–2975, Nov. 2010.
- [39] S. Rose, A. Misharin, and H. Perlman, "A novel Ly6C/Ly6G-based strategy to analyze the mouse splenic myeloid compartment," *Cytometry Part A*, vol. 81A, no. 4, pp. 343–350, Apr. 2012.
- [40] N. R. Styn, T. L. Hall, J. B. Fowlkes, C. A. Cain, and W. W. Roberts, "Histotripsy of renal implanted VX-2 tumor in a rabbit model: Investigation of metastases," *Urology*, vol. 80, no. 3, pp. 724–729, Sep. 2012.
- [41] G. R. Schade *et al.*, "Histotripsy focal ablation of implanted prostate tumor in an ACE-I canine cancer model," *J. Urol.*, vol. 188, no. 5, pp. 1957–1964, Nov. 2012.
- [42] T. Worlikar *et al.*, "Non-invasive orthotopic liver tumor ablation using histotripsy in an *in vivo* rodent hepatocellular carcinoma (HCC) model," in *Proc. Cofn. Soc. Interventional Oncol.*, Boston, MA, USA, 2019, pp. 1–4.
- [43] J. V. Jove *et al.*, "Phase I study of safety and efficacy of hepatic histotripsy: Preliminary results of first in man experience with robotically-assisted sonic therapy," in *Proc. Int. Soc. Therapeutic Ultrasound*, Barcelona, Spain, 2019, pp. 1–7.
- [44] D. S. Pisetsky, "The origin and properties of extracellular DNA: From PAMP to DAMP," *Clin. Immunol.*, vol. 144, no. 1, pp. 32–40, Jul. 2012.
- [45] J. P. Erinjeri and T. W. I. Clark, "Cryoablation: Mechanism of action and devices," *J. Vascular Interventional Radiol.*, vol. 21, no. 8, pp. S187–S191, Aug. 2010.
- [46] K. F. Chu and D. E. Dupuy, "Thermal ablation of tumours: Biological mechanisms and advances in therapy," *Nature Rev. Cancer*, vol. 14, no. 3, pp. 199–208, Mar. 2014.
- [47] E. Vlaisavljevich, T. Gerhardson, T. Hall, and Z. Xu, "Effects off-number on the histotripsy intrinsic threshold and cavitation bubble cloud behavior," *Phys. Med. Biol.*, vol. 62, no. 4, pp. 1269–1290, Feb. 2017, doi: [10.1088/1361-6560/aa54c7](https://doi.org/10.1088/1361-6560/aa54c7).
- [48] E. Vlaisavljevich *et al.*, "Effects of ultrasound frequency and tissue stiffness on the histotripsy intrinsic threshold for cavitation," *Ultrasound Med. Biol.*, vol. 41, no. 6, pp. 1651–1667, Jun. 2015.
- [49] E. Vlaisavljevich, A. Maxwell, M. Warnez, E. Johnsen, C. A. Cain, and Z. Xu, "Histotripsy-induced cavitation cloud initiation thresholds in tissues of different mechanical properties," *IEEE Trans. Ultrason., Ferroelectr., Freq. Control*, vol. 61, no. 2, pp. 341–352, Feb. 2014, doi: [10.1109/TUFFC.2014.6722618](https://doi.org/10.1109/TUFFC.2014.6722618).
- [50] A. D. Maxwell, C. A. Cain, T. L. Hall, J. B. Fowlkes, and Z. Xu, "Probability of cavitation for single ultrasound pulses applied to tissues and tissue-mimicking materials," *Ultrasound Med. Biol.*, vol. 39, no. 3, pp. 449–465, Mar. 2013.
- [51] D. Pisetsky, "Cell death in the pathogenesis of immune-mediated diseases: The role of HMGB1 and DAMP-PAMP complexes," *Swiss Med. Weekly*, vol. 141, p. w13256, Aug. 2011.
- [52] E. Venereau, M. Schiraldi, M. Ugucioni, and M. E. Bianchi, "HMGB1 and leukocyte migration during trauma and sterile inflammation," *Mol. Immunol.*, vol. 55, no. 1, pp. 76–82, Aug. 2013.
- [53] N. Haque *et al.*, "Role of the CXCR4-SDF1-HMGB1 pathway in the directional migration of cells and regeneration of affected organs," *World J. Stem Cells*, vol. 12, no. 9, p. 938, 2020.
- [54] S. Ying, X. Xiao, T. Chen, and J. Lou, "PPAR ligands function as suppressors that target biological actions of HMGB1," *PPAR Res.*, vol. 2016, pp. 1–10, 2016.
- [55] L. Piqueras *et al.*, "Activation of PPAR β/δ induces endothelial cell proliferation and angiogenesis," *Arteriosclerosis, Thrombosis, Vascular Biol.*, vol. 27, no. 1, pp. 63–69, 2007.
- [56] A. Lapeyre-Prost *et al.*, "Immunomodulatory activity of VEGF in cancer," in *International Review of Cell and Molecular Biology*, vol. 330. Amsterdam, The Netherlands: Elsevier, 2017, pp. 295–342.
- [57] J. Zhou, Z. Tang, S. Gao, C. Li, Y. Feng, and X. Zhou, "Tumor-associated macrophages: Recent insights and therapies," *Frontiers Oncol.*, vol. 10, p. 188, Feb. 2020.
- [58] G. J. Szebeni, C. Vizler, K. Kitajka, and L. G. Puskas, "Inflammation and cancer: Extra- and intracellular determinants of tumor-associated macrophages as tumor promoters," *Mediators Inflammation*, vol. 2017, pp. 1–13, Oct. 2017.
- [59] B. Chaudhary and E. Elkord, "Regulatory T cells in the tumor microenvironment and cancer progression: Role and therapeutic targeting," *Vaccines*, vol. 4, no. 3, p. 28, Aug. 2016.
- [60] A. Kumar, K. Chamoto, P. S. Chowdhury, and T. Honjo, "Tumors attenuating the mitochondrial activity in T cells escape from PD-1 blockade therapy," *ELife*, vol. 9, Mar. 2020, Art. no. e52330.
- [61] C. He, X. Huang, Y. Zhang, X. Lin, and S. Li, "T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer," *Clin. Transl. Med.*, vol. 10, no. 2, p. e39, Jun. 2020.



Alissa Hendricks-Wenger received the B.S. degree in bioengineering from The University of Texas at Arlington, Arlington, TX, USA, in 2016, and the Ph.D. degree in translational biology, medicine, and health from Virginia Tech, Blacksburg, VA, USA, in 2021. She is currently pursuing the D.O. degree with the Lincoln Memorial University—DeBusk College of Osteopathic Medicine, Knoxville, TN, USA.

Her current research interests include ultrasound for noninvasive tissue ablation, cancer, tissue engineering, and cancer immunology.

Jacqueline Sereno is currently pursuing the B.S. degree in biology with Virginia Tech, Blacksburg, VA, USA.

She currently conducts research with the Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg.

Jessica Gannon received the B.S. degree in mechanical engineering from Virginia Tech, Blacksburg, VA, USA, in 2021, where she is currently pursuing the Ph.D. degree in biomedical engineering and mechanics.

Ms. Gannon's selected honors include an NSF Graduate Research Fellowship.

Allison Zeher received the B.S. degree in biochemistry from Virginia Tech, Blacksburg, VA, USA, in 2019.

She is currently working at the National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.



Rebecca M. Brock received the B.S. degree in biology and German studies from the University of Kentucky, Lexington, KY, USA, in 2014, and the Ph.D. degree in translational biology, medicine, and health from Virginia Tech, Blacksburg, VA, USA, in 2020, with her dissertation work on studying the biological and immunological impacts of irreversible electroporation-based technologies on pancreatic cancer.

She currently holds a post-doctoral position at the Baylor College of Medicine Department of Pediatrics, Center for Cell and Gene Therapy, Houston, TX, USA, where she is investigating cell therapy treatments for pediatric solid malignancies.



Natalie Beitel-White (Student Member, IEEE) received the B.S. degree in electrical engineering from The University of Tennessee, Knoxville, TN, USA, in 2016, and the Ph.D. degree in electrical engineering from Virginia Tech, Blacksburg, VA, USA, in 2021.

Her research interests include bioelectronics, bioimpedance, and pulsed electric fields for non-thermal tumor ablation.



Alexander Simon received the B.S. degree in engineering science and mechanics from Virginia Tech, Blacksburg, VA, USA, in 2019, where he is currently pursuing the Ph.D. degree in engineering mechanics.

His current research interest includes focused ultrasound for noninvasive tissue ablation and acoustic cavitation.



Rafael V. Davalos (Member, IEEE) received the B.S. degree from Cornell University, Ithaca, NY, USA, in 1994, and the M.S. and Ph.D. degrees from the University of California at Berkeley, Berkeley, CA, USA, in 1995 and 2002, respectively.

He is currently an Endowed Professor with the Virginia Tech-Wake Forest University School of Biomedical Engineering and Sciences, Virginia Tech, Blacksburg, VA, USA. He holds adjunct appointments in mechanical engineering at the

Wake Forest Comprehensive Cancer Center, Wake Forest, NC, USA, and the Wake Forest Institute for Regenerative Medicine, Wake Forest. Prior to his career as a faculty member, he was a Principal Member of the Technical Staff at Sandia National Laboratories.

Dr. Davalos is an ASME Fellow, AIMBE Fellow, and Coulter Fellow. He is also the 2021 recipient of the ASME Van C. Mow Medal.

Sheryl Coutermarsh-Ott received the B.S. degree in biology from the University of Maryland, College Park, MD, USA, in 2003, and the D.V.M. degree and the Ph.D. degree in biomedical and veterinary sciences from the Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, USA, in 2011 and 2017, respectively.

She received specialty training in veterinary anatomic pathology from the College of Veterinary Medicine, University of Georgia, Athens, GA, USA, and achieved board certification in 2014. She is currently an Anatomic Pathologist with the Virginia-Maryland College of Veterinary Medicine and the Virginia Tech Veterinary Teaching Hospital, Blacksburg, VA, USA.



Eli Vlasisavljevic conducted his graduate degrees at the Histotripsy Lab, University of Michigan, Ann Arbor, MI, USA, from 2010 to 2015, and then spent two years working on the development of histotripsy for the treatment of liver cancer at HistoSonics from 2015 to 2017. He is currently an Assistant Professor of biomedical engineering and mechanics with the Virginia Polytechnic Institute and State University, Blacksburg, VA, USA. His research interests include focused ultrasound,

noninvasive tissue ablation (HIFU and histotripsy), cavitation physics, nanoparticle-mediated histotripsy (NMH), biomaterials, tissue regeneration, cancer, noninvasive neuromodulation, and clinical translation. More information about his research group can be found at <https://ultrasound-lab.beam.vt.edu/>.



Irving Coy Allen received the B.S. degree in biology from East Carolina University, Greenville, NC, USA, in 1997, the M.S. degree in biology from the University of North Carolina at Greensboro, Greensboro, NC, in 2000, the Ph.D. degree in genetics and molecular biology from the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA, in 2006, and the M.B.A. degree in bioscience management from North Carolina State University, Raleigh, NC, in 2012.

He was a Post-Doctoral Fellow with the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, from 2007 to 2011. He is currently a tenured Associate Professor with the Department of Biomedical Sciences and Pathobiology, Virginia-Maryland College of Veterinary Medicine, Blacksburg, VA, USA. His current research interests include cancer immunology, animal models of innate immunity, animal models of allergic diseases, and host-pathogen interactions.